Novel Biologics and B-Cell Depletion: Fueling IgG4-Related Disease market growth
The therapeutic segment is a major engine for IgG4-Related Disease market growth, largely driven by the adoption of biologic Product Types. While glucocorticoids remain the cornerstone of initial treatment Standard Protocols, their significant long-term side effects in chronic conditions like IgG4-RD necessitate the use of steroid-sparing agents. Monoclonal...
0 Kommentare 0 Anteile 72 Ansichten 0 Vorschau